• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    EXL Announces Appointment of Andreas Fibig to Board of Directors

    1/12/23 4:01:00 PM ET
    $EXLS
    $IFF
    $NVO
    Business Services
    Consumer Discretionary
    Major Chemicals
    Industrials
    Get the next $EXLS alert in real time by email

    NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ:EXLS), a leading global data analytics and digital operations and solutions company, today announced that Andreas Fibig, a seasoned global executive with a strong record of innovation across industries and geographies, has been appointed to EXL's Board of Directors as an independent director effective Jan. 10, 2023. Fibig will be a member of the Board's Audit and Nominating and Governance Committees.

    "Andreas is a distinguished global business leader with more than 25 years of international health care, pharmaceutical, and consumer industry experience," said Vikram S. Pandit, Chairman of the Board of EXL. "We look forward to the insights and contributions Andreas will bring to the Board and leadership team as the company executes on its growth strategy."

    EXL Vice Chairman and Chief Executive Officer Rohit Kapoor said, "We are delighted to welcome Andreas to our Board of Directors. His years of experience leading large global organizations will provide us with valuable insight and perspective as we rapidly scale EXL into the dominant global player in analytics and digital operations. Andreas also brings a unique combination of experience in international markets along with a deep understanding of U.S. business, which will benefit EXL as we continue our geographic expansion, particularly in Europe."

    "I'm truly excited to join the EXL Board at this stage in the company's journey," said Fibig. "EXL's transformation to a data-led analytics and digital operations company has resulted in remarkable growth and significant improvement in profitability. I look forward to working with the Board and management team to help the company continue its growth trajectory as well as create sustainable competitive advantage through its digital strategy. I am also honored to be part of an organization that focuses on sustainability as part of its enterprise strategy, and I'm excited to help further those efforts."

    Fibig spent 10 years with International Flavors & Fragrances (NYSE:IFF), an industry leader in food ingredients, beverage, scent, health care and biosciences, including seven years as Chairman and CEO. There, he established a record of driving strong growth as well as leading the company through significant transformation, including the integration of DuPont Nutrition & Biosciences following a merger. Prior to that, he served as president and chairman of the board of management for Bayer Health Care Pharmaceuticals, where he was the chief executive responsible for Bayer's global health care and pharmaceutical business. He currently serves on the board of Novo-Nordisk A/S (NYSE:NVO), where he is an independent director and member of the Research and Development Committee. He also serves as a director of Indigo Agriculture and EvodiaBio, which are private companies. He previously served on the board of Bunge Limited, a leading global agribusiness and food company.

    About EXL

    EXL (NASDAQ:EXLS) is a leading data analytics and digital operations and solutions company that partners with clients to improve business outcomes and unlock growth. By bringing together deep domain expertise with robust data, powerful analytics, cloud, artificial intelligence ("AI") and machine learning ("ML"), we create agile, scalable solutions and execute complex operations for the world's leading corporations in industries including insurance, healthcare, banking and financial services, media, and retail, among others. Focused on driving faster decision-making and transforming operating models, EXL was founded on the core values of innovation, collaboration, excellence, integrity and respect. Headquartered in New York, our team is over 43,100 strong, with more than 50 offices spanning six continents. For more information, visit www.exlservice.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to EXL's operations and business environment, all of which are difficult to predict and many of which are beyond EXL's control. Forward-looking statements include information concerning EXL's possible or assumed future results of operations, including descriptions of its business strategy. These statements may include words such as "may," "will," "should," "believe," "expect," "anticipate," "intend," "plan," "estimate" or similar expressions. These statements are based on assumptions that we have made in light of management's experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although EXL believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect EXL's actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors, which include our ability to successfully close and integrate strategic acquisitions, our ability to respond to and manage public health crises, including the outbreak and continued effects of COVID-19 pandemic, are discussed in more detail in EXL's filings with the Securities and Exchange Commission, including EXL's Quarterly Report on Form 10-Q and Annual Report on Form 10-K. These risks could cause actual results to differ materially from those implied by forward-looking statements in this release. You should keep in mind that any forward-looking statement made herein, or elsewhere, speaks only as of the date on which it is made. New risks and uncertainties come up from time to time, and it is impossible to predict these events or how they may affect EXL. EXL has no obligation to update any forward-looking statements after the date hereof, except as required by federal securities laws.

    © 2023 ExlService Holdings, Inc. All rights reserved. For more information go to www.exlservice.com/legal-disclaimer

    Contacts

    Media 

    Keith Little

    Senior Manager, Media Relations

    +1 703-598-0980 

    [email protected]

    Investor Relations

    John Kristoff

    +1 212 209 4613

    [email protected]



    Primary Logo

    Get the next $EXLS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EXLS
    $IFF
    $NVO

    CompanyDatePrice TargetRatingAnalyst
    International Flavors & Fragrances Inc.
    $IFF
    5/8/2025$84.00Equal Weight → Overweight
    Barclays
    Novo Nordisk A/S
    $NVO
    4/17/2025$64.00Outperform → Market Perform
    BMO Capital Markets
    Novo Nordisk A/S
    $NVO
    3/13/2025Hold → Buy
    Kepler
    Novo Nordisk A/S
    $NVO
    3/3/2025Buy → Hold
    Stifel
    International Flavors & Fragrances Inc.
    $IFF
    2/20/2025$77.00Buy → Sell
    CFRA
    Novo Nordisk A/S
    $NVO
    2/12/2025Equal-Weight
    Morgan Stanley
    International Flavors & Fragrances Inc.
    $IFF
    1/7/2025Hold → Buy
    Argus
    Novo Nordisk A/S
    $NVO
    1/6/2025Underperform → Mkt Perform
    Bernstein
    More analyst ratings

    $EXLS
    $IFF
    $NVO
    Leadership Updates

    Live Leadership Updates

    See more
    • IFF Appoints Two New Fine Fragrance Perfumers

      Alexandra Carlin and Alex Lee join the Paris-based fine fragrance team, bringing fresh artistic perspectives PARIS, Nov. 4, 2024 /PRNewswire/ -- IFF (NYSE:IFF) proudly welcomes Alexandra Carlin as Senior Fine Fragrance Perfumer and Alex Lee as Fine Fragrance Perfumer to its Paris-based team. These strategic additions aim to enhance the Company's creative prowess in the world of perfumery. "We're excited for the talent and creative energy that Alexandra and Alex will bring to IFF Scent," said Sabrya Meflah, president, Fine Fragrance, IFF. "Alexandra's ability to translate deep

      11/4/24 4:00:00 AM ET
      $IFF
      Major Chemicals
      Industrials
    • IFF Pharma Solutions Brings New Innovations and Excipient Excellence to CPHI 2024

      NEW YORK, Sept. 26, 2024 /PRNewswire/ -- IFF (NYSE:IFF) Pharma Solutions is proud to announce its more than 75-year legacy as an excipient manufacturer with new product launches and technologies for the pharmaceutical and biotech industries. Celebrating this pivotal milestone, IFF will spotlight its latest solutions for nitrosamine mitigation at CPHI 2024, Milan, Oct. 8-10, booth 6B10. The range includes a new portfolio of low nitrite excipients and ultrapure alginate biopolymers for next-generation therapeutic development. "We are unveiling groundbreaking technologies that re

      9/26/24 9:00:00 AM ET
      $IFF
      Major Chemicals
      Industrials
    • Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

      9/24/24 8:00:00 AM ET
      $ALGS
      $HAE
      $NVO
      $PLRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations

    $EXLS
    $IFF
    $NVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director O'Byrne Kevin bought $522,833 worth of shares (6,500 units at $80.44) (SEC Form 4)

      4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

      3/6/25 5:13:59 PM ET
      $IFF
      Major Chemicals
      Industrials
    • CEO Fyrwald J Erik bought $2,005,878 worth of shares (25,000 units at $80.24), increasing direct ownership by 581% to 29,300 units (SEC Form 4)

      4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

      3/5/25 4:08:27 PM ET
      $IFF
      Major Chemicals
      Industrials

    $EXLS
    $IFF
    $NVO
    SEC Filings

    See more
    • SEC Form 6-K filed by Novo Nordisk A/S

      6-K - NOVO NORDISK A S (0000353278) (Filer)

      5/9/25 8:12:45 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by ExlService Holdings Inc.

      144 - ExlService Holdings, Inc. (0001297989) (Subject)

      5/8/25 12:19:05 PM ET
      $EXLS
      Business Services
      Consumer Discretionary
    • SEC Form 8-K filed by International Flavors & Fragrances Inc.

      8-K - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Filer)

      5/7/25 4:34:15 PM ET
      $IFF
      Major Chemicals
      Industrials

    $EXLS
    $IFF
    $NVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ExlService Holdings Inc.

      SC 13G/A - ExlService Holdings, Inc. (0001297989) (Subject)

      11/12/24 9:55:17 AM ET
      $EXLS
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G/A filed by International Flavors & Fragrances Inc. (Amendment)

      SC 13G/A - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Subject)

      3/8/24 4:44:49 PM ET
      $IFF
      Major Chemicals
      Industrials
    • SEC Form SC 13G/A filed by International Flavors & Fragrances Inc. (Amendment)

      SC 13G/A - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Subject)

      2/13/24 5:07:58 PM ET
      $IFF
      Major Chemicals
      Industrials

    $EXLS
    $IFF
    $NVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IFF Completes Divestiture of Nitrocellulose Business

      IFF (NYSE:IFF) today announced that it has completed the divestiture of its nitrocellulose business, including Walsrode Industrial Park in lower Saxony, Germany, to Czechoslovak Group (CSG). The business manufactures nitrocellulose strictly for industrial purposes, serving customers primarily in coatings and printing inks, and had been part of IFF's Pharma Solutions business unit. "The divestiture of our nitrocellulose business builds upon our deleveraging journey and enables us to focus on our core businesses," said Erik Fyrwald, IFF CEO. "I'd like to thank our nitrocellulose colleagues for their dedication and wish them continued success as part of CSG." Welcome to IFF At IFF (NYSE:IFF)

      5/9/25 8:00:00 AM ET
      $IFF
      Major Chemicals
      Industrials
    • EXL to participate in upcoming investor conferences

      NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ:EXLS), a leading data and AI company, today announced Maurizio Nicolelli, executive vice president, chief financial officer, and John Kristoff, vice president, head investor relations, are expected to participate at the following investor conferences: 20th Annual Needham Technology, Media, & Consumer 1x1 Conference, Monday, May 12, 2025, VirtualTD Cowen 53nd Annual Technology, Media & Telecom Conference, Thursday, May 29, 2025, New York, NY, (presentation at 10:50 AM EDT)Baird 2025 Global Consumer, Technology & Services Conference, Thursday, June 5, 2025, New York, NY (presentation at 2:00 PM EDT)Live audio webca

      5/8/25 8:48:14 AM ET
      $EXLS
      Business Services
      Consumer Discretionary
    • IFF Reports First Quarter 2025 Results

      IFF (NYSE:IFF) reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Consolidated Summary: Reported (GAAP)   Adjusted (Non-GAAP)1 Sales   Loss Before Taxes*   EPS   Operating EBITDA   Operating EBITDA Margin   EPS ex Amortization $2.8 B   $(994) M   $(3.98)   $578 M   20.3%   $1.20 * Impacted by an impairment of goodwill of $1.15B in Food Ingredients Management Commentary "IFF delivered solid first quarter results, driven by disciplined execution and broad-based growth across most of our business," said IFF CEO Erik Fyrwald. "Our growth, combined with ongoing product

      5/6/25 4:20:00 PM ET
      $IFF
      Major Chemicals
      Industrials

    $EXLS
    $IFF
    $NVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Intl Flavors upgraded by Barclays with a new price target

      Barclays upgraded Intl Flavors from Equal Weight to Overweight and set a new price target of $84.00

      5/8/25 8:24:21 AM ET
      $IFF
      Major Chemicals
      Industrials
    • Novo Nordisk A/S downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded Novo Nordisk A/S from Outperform to Market Perform and set a new price target of $64.00

      4/17/25 8:30:12 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novo Nordisk A/S upgraded by Kepler

      Kepler upgraded Novo Nordisk A/S from Hold to Buy

      3/13/25 8:17:45 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EXLS
    $IFF
    $NVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman & CEO Kapoor Rohit gifted 5,000 shares (SEC Form 4)

      4 - ExlService Holdings, Inc. (0001297989) (Issuer)

      5/6/25 5:31:23 PM ET
      $EXLS
      Business Services
      Consumer Discretionary
    • Director Studenmund Jaynie M sold $692,987 worth of shares (14,580 units at $47.53), closing all direct ownership in the company (SEC Form 4)

      4 - ExlService Holdings, Inc. (0001297989) (Issuer)

      5/6/25 5:30:51 PM ET
      $EXLS
      Business Services
      Consumer Discretionary
    • SEC Form 4 filed by Director Ferraro John Francis

      4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

      5/5/25 5:58:11 PM ET
      $IFF
      Major Chemicals
      Industrials

    $EXLS
    $IFF
    $NVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

      For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr

      3/8/24 2:00:18 PM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EXLS
    $IFF
    $NVO
    Financials

    Live finance-specific insights

    See more
    • IFF Reports First Quarter 2025 Results

      IFF (NYSE:IFF) reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Consolidated Summary: Reported (GAAP)   Adjusted (Non-GAAP)1 Sales   Loss Before Taxes*   EPS   Operating EBITDA   Operating EBITDA Margin   EPS ex Amortization $2.8 B   $(994) M   $(3.98)   $578 M   20.3%   $1.20 * Impacted by an impairment of goodwill of $1.15B in Food Ingredients Management Commentary "IFF delivered solid first quarter results, driven by disciplined execution and broad-based growth across most of our business," said IFF CEO Erik Fyrwald. "Our growth, combined with ongoing product

      5/6/25 4:20:00 PM ET
      $IFF
      Major Chemicals
      Industrials
    • IFF Declares Dividend for Second Quarter 2025

      IFF (NYSE:IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 11, 2025 to shareholders of record as of June 20, 2025. Welcome to IFF At IFF (NYSE:IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Res

      5/1/25 4:15:00 PM ET
      $IFF
      Major Chemicals
      Industrials
    • EXL Reports 2025 First Quarter Results

      2025 First Quarter Revenue of $501.0 Million, up 14.8% year-over-yearQ1 Diluted EPS (GAAP) (1) of $0.40, up 38.3% from $0.29 in Q1 of 2024Q1 Adjusted Diluted EPS (Non-GAAP) (1) of $0.48, up 26.9% from $0.38 in Q1 of 2024 NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ:EXLS), a global data and AI company, today announced its financial results for the quarter ended March 31, 2025. Chairman and Chief Executive Officer Rohit Kapoor said, "We are pleased with our first quarter results and strong start to the year, as we delivered revenue and adjusted diluted EPS growth of 15% and 27% respectively. Our strong business momentum underscores the successful execution

      4/29/25 4:01:00 PM ET
      $EXLS
      Business Services
      Consumer Discretionary